Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges [Phase 2]

View source ↗

Summary

Phase II study evaluating oral ceritinib in ALK-positive non-small cell lung cancer with brain/leptomeningeal involvement; trial completed with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ceritinib (ceritinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: ALK-positive Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-02-21